Memorial Sloan-Kettering Cancer Center (MSKCC) Memorial Sloan Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through in-patient and out-patient care, clinical and research training programs, and a broad spectrum of research activities. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental Biology, Genomic Integrity, and Molecular Structure);Bridge Disciplines (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences), and Patient-Oriented Research (Clinical Research and Prevention, Control, and Population Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the ten research programs depends on services provided by 34 core facilities, 19 of which will receive funding from the Cancer Center Support Grant (CCSG). During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs;therefore, an expanded budget is requested to establish the laboratories of new investigators in several fields of inquiry and to support the core facilities which have grown to support the needs of the research enterprise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-47S6
Application #
8733796
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2014-12-31
Budget Start
2012-01-09
Budget End
2014-12-31
Support Year
47
Fiscal Year
2013
Total Cost
$238,405
Indirect Cost
$97,002
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Kamboj, Mini; Cohen, Nina; Huang, Yao-Ting et al. (2018) Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant :
Agbu, Stephanie O; Liang, Yinwen; Liu, Aimin et al. (2018) The small GTPase RSG1 controls a final step in primary cilia initiation. J Cell Biol 217:413-427
Assel, Melissa J; Li, Fan; Wang, Ying et al. (2018) Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study. Ophthalmology 125:391-397
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Yeung, K Simon; Hernandez, Marisol; Mao, Jun J et al. (2018) Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance. Phytother Res 32:865-891
Audenet, Fran├žois; Vertosick, Emily A; Fine, Samson W et al. (2018) Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. J Urol 199:961-968
Petrovic, Ivana; Rosen, Evan B; Matros, Evan et al. (2018) Oral rehabilitation of the cancer patient: A formidable challenge. J Surg Oncol 117:1729-1735
Balakrishnan, Mridula; Baylies, Mary K (2018) Myonuclear Positioning and Aneurysms Are LINC'd by Ariande. Dev Cell 45:149-150
McKnight, Brooke N; Kuda-Wedagedara, Akhila N W; Sevak, Kuntal K et al. (2018) Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). Sci Rep 8:9043
Thor, Maria; Jackson, Andrew; Zelefsky, Michael J et al. (2018) Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy. Radiother Oncol 127:88-95

Showing the most recent 10 out of 8799 publications